However, the response rate to sorafenib in HCC is very low (2–3%) and it has been shown that activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling pathway mediates acquired resistance to sorafenib in HCC (4). The gene discussed is AKT1; the disease is hepatocellular carcinoma.